Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
140.55
-0.42 (-0.30%)
Jan 28, 2026, 1:10 PM EST - Market open
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
$1,652,670
Profits / Employee
$460,795
Market Cap
174.38B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
| Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
| Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
| Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
| Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
| Jan 31, 2015 | 7,000 | 900 | 14.75% |
| Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
| Jan 31, 2013 | 5,000 | 500 | 11.11% |
| Jan 31, 2012 | 4,500 | 500 | 12.50% |
| Jan 31, 2011 | 4,000 | 148 | 3.84% |
| Jan 31, 2010 | 3,852 | 411 | 11.94% |
| Jan 31, 2009 | 3,441 | 462 | 15.51% |
| Jan 31, 2008 | 2,979 | 464 | 18.45% |
| Jan 31, 2007 | 2,515 | 615 | 32.37% |
| Jan 31, 2006 | 1,900 | 246 | 14.87% |
| Feb 28, 2005 | 1,654 | 229 | 16.07% |
| Feb 27, 2004 | 1,425 | 175 | 14.00% |
| Feb 28, 2003 | 1,250 | 250 | 25.00% |
| Feb 28, 2002 | 1,000 | 150 | 17.65% |
| Feb 28, 2001 | 850 | 90 | 11.84% |
| Dec 31, 1999 | 760 | 467 | 159.39% |
| Dec 31, 1998 | 293 | 4 | 1.38% |
| Dec 31, 1997 | 289 | 41 | 16.53% |
| Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| GSK plc | 68,629 |
GILD News
- 21 hours ago - Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 - Business Wire
- 6 days ago - New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer - Business Wire
- 8 days ago - Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced - Seeking Alpha
- 11 days ago - Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade) - Seeking Alpha
- 15 days ago - Gilead Sciences: From All-Time Highs To Higher Highs - Seeking Alpha
- 15 days ago - Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says - Reuters
- 15 days ago - Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate - Business Wire